Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome.
about
Eculizumab in a child with atypical haemolytic uraemic syndrome and haemophagocytic lymphohistiocytosis triggered by cytomegalovirus infection.Atypical hemolytic-uremic syndrome due to complement factor I mutation.Atypical hemolytic uremic syndrome and eculizumab therapy in children.Cutaneous Vasculitis and Digital Ischaemia Caused by Heterozygous Gain-of-Function Mutation in
P2860
Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome.
description
2016 nî lūn-bûn
@nan
2016 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Current evidence on the discon ...... l haemolytic uraemic syndrome.
@ast
Current evidence on the discon ...... l haemolytic uraemic syndrome.
@en
type
label
Current evidence on the discon ...... l haemolytic uraemic syndrome.
@ast
Current evidence on the discon ...... l haemolytic uraemic syndrome.
@en
prefLabel
Current evidence on the discon ...... l haemolytic uraemic syndrome.
@ast
Current evidence on the discon ...... l haemolytic uraemic syndrome.
@en
P2093
P2860
P356
P1476
Current evidence on the discon ...... l haemolytic uraemic syndrome.
@en
P2093
Christoph Gasteyger
Fernando de Alvaro Moreno
Ingela Fehrman
Karine Hadaya
Manuel Macia
Nils Heyne
P2860
P304
P356
10.1093/CKJ/SFW115
P577
2016-12-22T00:00:00Z